Objective: To investigate the clinical, laboratory and histological manifestations of patients who received illegal injections of foreign substances for cosmetic purposes.
Patients and methods: We studied patients who met the following inclusion criteria: 1) history of application of foreign substances for cosmetic purposes, 2) clinical data of autoimmune disease or non-specific autoimmune manifestation (i.e. arthralgias, myalgia, malaise, fever, and weight loss), 3) detection of autoantibodies in patients’ sera, 4) histological evidence of chronic inflammation and/or granulomatous reaction to foreign body.
Results: Fifty female patients aged 44.4 ± 10 years were studied. The mean time between application of foreign substances and onset of symptoms was 4.5 ± 4.3 years. Patients were followed for 12 ± 7.5 years. Forty-one patients were injected with mineral oil, nine patients received other substances: three iodine gadital, one guayacol, one guayacol plus silicone fluid, two collagen, two silicone fluid. The sites of application were: buttocks (36), legs and/or thighs (11), breasts (eight) hands and face (one), face (two) (seven patients received an injection to more than one site). Thirty patients presented with non-specific autoimmune manifestations, whereas 20 patients fulfilled the criteria for a defined autoimmune disease such as systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, overlap syndrome, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune hepatitis, and ulcerative colitis.
Conclusions: Cases of human adjuvant disease following illegal injections of oil substances for cosmetic purposes are reported. Patients presented with defined autoimmune diseases as well as with non-specific autoimmune manifestations. Illegal injection of these substances could lead to serious local and systemic complications, even to death. These cases represent another model of Autoimmune/inflammatory Syndrome Induced by Adjuvants (ASIA). The use of these substances should be prohibited.
MiyoshiKMiyaokaTKobayashiY. Hypergammaglobulinemia by prolonged adjuvancity in men. Disorders developed after augmentation mammoplasty. J Jap Med1964; 2122: 9–14.
2.
MiyoshiKShiragamiHYoshidaK. Adjuvant disease of men. Clin Immunol1973; 5: 785–794.
3.
KumagaiYShiokawaYMedsgerTA. Clinical spectrum of connective tissue disease after cosmetic surgery. Arthritis Rheum1984; 27: 1–12.
4.
CabralARAlcocer-VarelaJOrozco-TopeteR. Clinical, histopathological, immunological and fibroblast studies in 30 patients with subcutaneous injections of modelants including silicone and mineral oils. Rev Invest Clin1994; 46: 257–266.
5.
GabrielSEO’ FallonWMKurlandLT. Risk of connective tissue diseases and other disorders after breast implantation. N Engl J Med1994; 330: 1697–1702.
6.
Sánchez-GuerreroJSchurPHSergentJS. Silicone Breast implants and rheumatic disease - Clinical, Immunologic, and Epidemiologic Studies. Arthritis Rheum1994; 37: 158–168.
7.
JanowskyECKupperLLHulkaBS. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N Engl J Med2000; 342: 781–790.
8.
HennekensCHLeeIMCookNR. Self-reported breast implants and connective-tissue diseases in female health professionals. A retrospective cohort study. JAMA1996; 275: 616–621.
9.
BassetoFVindigniVScarpaC. Breast prostheses and connective tissue disease CTD: myth or reality?Aest Plast Surg2010; 34: 257–263.
10.
HajduSDAgmon-LevinNShoenfeldY. Silicone and autoimmunity. Eur J Clin Invest2011; 41: 203–211.
MeroniPL. Autoimmune or auto-inflammatory syndrome induced by adjuvants (ASIA): Old truths and a new syndrome?J Autoimmun2011; 36: 1–3.
13.
ArnettFCEdworthySMBlochDA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum1988; 31: 315–324.
14.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
15.
Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum1980; 23: 581–590.
16.
BohanAPeterJB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med1975; 292: 344–347.
17.
VitaliCBombardieriSMoutsopoulosHM. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum1993; 36: 340–347.
18.
WolfeFClauwDJFitzcharlesMA. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken)2010; 62: 600–610.
19.
BeharTAAndersonEEBarwickWJ. Sclerosing lipogranulomatosis: a case report of scrotal injection of automobile transmission fluid and literature review of subcutaneous injection of oils. Plast Reconstr Surg1993; 91: 352–361.
20.
Ortiz MonasterioFTrigosY. Management of patients with complications from injections of foreign material into the breast. Plast Reconstr Surg1972; 50: 42–47.
21.
HageJJKanhaiRCOenAL. The devastating outcome of massive subcutaneous injection of highly viscous fluids in male-to-female transsexuals. Plast Reconstr Surg2001; 107: 734–741.
22.
SallesAGLotierzoPHGemperliR. Complications after polymethylmethacrylate injections: report of 32 cases. Plast Reconstr Surg2008; 121: 1811–1820.
23.
KleinauSErlandssonHKlareskogL. Percutaneous exposure of adjuvant oil causes arthritis in DA rats. Clin Exp Immunol1994; 96: 281–284.
24.
WaksmanBH. Immune regulation in adjuvant disease and other arthritis models: relevance to pathogenesis of chronic arthritis. Scand J Immunol2002; 56: 12–34.
25.
IsraeliEAgmon-LevinNBlankM. Adjuvants and autoimmunity. Lupus2009; 18: 1217–1225.
26.
CarvalhoJFBarrosSM. ASIA or Shoenfeld's syndrome: a novel autoimmune syndrome?Rev Bras Reumatol2010; 50: 487–488.
27.
CerveraR. ASIA: a new systemic autoimmune syndrome?Lupus2011; 20: 665–666.
